Ascentage Pharma Group International
HKEX:6855
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
15.7
47.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Ascentage Pharma Group International
Ascentage Pharma Group International
Income from Continuing Operations
Ascentage Pharma Group International
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ascentage Pharma Group International
HKEX:6855
|
Income from Continuing Operations
-¥925.7m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Income from Continuing Operations
-¥6.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Income from Continuing Operations
-¥1.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Income from Continuing Operations
¥1.2B
|
CAGR 3-Years
22%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Income from Continuing Operations
¥3.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
12%
|
CAGR 10-Years
39%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Income from Continuing Operations
¥1.9B
|
CAGR 3-Years
62%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
Ascentage Pharma Group International
Glance View
Ascentage Pharma Group International Co., Ltd. develops and produces pharmaceutical products. The company is headquartered in Suzhou, Jiangsu and currently employs 613 full-time employees. The company went IPO on 2019-10-28. The firm focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The firm's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The firm conducts businesses within the domestic market and to overseas markets, including the United States.
See Also
What is Ascentage Pharma Group International's Income from Continuing Operations?
Income from Continuing Operations
-925.7m
CNY
Based on the financial report for Dec 31, 2023, Ascentage Pharma Group International's Income from Continuing Operations amounts to -925.7m CNY.
What is Ascentage Pharma Group International's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-22%
Over the last year, the Income from Continuing Operations growth was -5%. The average annual Income from Continuing Operations growth rates for Ascentage Pharma Group International have been -11% over the past three years , -22% over the past five years .
You don't have any saved screeners yet
